Strategies to Overcome Downstream Bottlenecks in Cell and Gene Therapy
Posted on September 27, 2018
Hemant Dhamne, PhD
Senior Research Scientist, Gene Therapy
Intas Biopharmaceuticals
Abstract The success of gene and cell therapy in clinical trials and recent FDA approval demands for robust platforms of upstream and downstream processes for viral vector production. The upstream stage comprises of processes leading to vector packaging and downstream comprises of processes for vect...
To read the full article and other articles in this issue, please register for a free account or log in.
We will not sell or give your information to a third party. See our Privacy Policy
Related Topics and Keywords
adeno-associated, gene therapy, Hemant Dhamne, human gene therapy, Intas Biopharmaceuticals, purification of recombinant adeno-associated
Subscribe to our FREE newsletter and WEBINAR UPDATES
We will not sell or give your information to a third party. See our Privacy Policy
